The Experts below are selected from a list of 2022 Experts worldwide ranked by ideXlab platform
Marcel C. Pasch - One of the best experts on this subject based on the ideXlab platform.
-
Reporting of outcomes in randomized controlled trials on Nail Psoriasis: a systematic review.
British Journal of Dermatology, 2018Co-Authors: C. I. Busard, Marcel C. Pasch, J. Y. C. Nolte, Ph.i. SpulsAbstract:BACKGROUND: Harmonization of outcome measures is needed to increase the value of clinical trials on Nail Psoriasis. OBJECTIVES: To provide the first step in core outcome set (COS) development for Nail Psoriasis. METHODS: A systematic review was performed to identify outcome instruments and corresponding outcome domains used in (ongoing) randomized controlled trials. RESULTS: Identified outcome domains included clinical signs, quality of life, symptoms and delivery of care. The Nail Psoriasis Severity Index (NAPSI) was the most commonly used measure to assess clinical signs (74% of studies). Other outcome instruments used included the Nail Area Severity score, composite fingerNail score, a Physician's Global Assessment, individual Nail features or a combination of these. Heterogeneity in type and reporting (e.g. NAPSI 50, NAPSI 75) of outcome instruments was high and characteristics were often insufficiently reported. In total 43% of studies assessed quality of life, with 3% of studies using a Nail Psoriasis-specific tool. Assessment of symptoms and delivery of care was limited. CONCLUSIONS: Heterogeneity in the type and reporting of Nail Psoriasis outcome instruments needs to be addressed in the process towards COS development. Sufficient reporting of instrument characteristics should be encouraged. As Nail Psoriasis is generally assessed secondarily to Psoriasis of the skin or joints, collaboration between different research groups in COS development is needed.
-
Subclinical enthesitis in Nail Psoriasis patients: a case-control study.
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2017Co-Authors: Karlijn M.g. Klaassen, Peter C.m. Van De Kerkhof, Marieke J.m. Ploegmakers, Willemijn M. Klein, Marcel C. PaschAbstract:BACKGROUND: Patients with Nail Psoriasis have a higher prevalence of psoriatic arthritis+ADs- however, the pathogenetic relationship between these two disorders is as yet unclear. Entheses have been suggested as disease epicenter, which might explain the pathogenesis on an anatomical level. OBJECTIVE: To contribute to the elucidation of the hypothesis as regards the anatomical link between Nail Psoriasis and psoriatic arthritis, with the extensor enthesis of the distal interphalangeal joint as the epicenter. METHODS: We conducted a cross-sectional cohort study, visualizing the distal interphalangeal (DIP) joints entheses of patients with fingerNail Psoriasis (n +AD0- 54), Psoriasis patients without Nail involvement (n +AD0- 32), and healthy controls (n +AD0- 32) using three-dimensional ultrasound. Patients with Nail Psoriasis underwent repeat imaging studies after one year. RESULTS: Individuals with Nail Psoriasis had significantly thicker radial entheses than Psoriasis patients without Nail involvement. However, there were no significant differences in entheseal thickness between adjacent Nails that were affected and those that were not (1.297 mm vs. 1.253 mm, p +AD0- 0.13). Follow-up after one year showed no significant differences in entheseal thickness in correlation with Nail Psoriasis activity. CONCLUSIONS: The present study provides evidence for subclinical enthesitis at the level of the DIP joint in patients with Nail Psoriasis. However, an anatomical correlation between Nail Psoriasis and psoriatic arthritis could not be confirmed.
-
Nail Psoriasis: A Review of Treatment Options
Drugs, 2016Co-Authors: Marcel C. PaschAbstract:Nail involvement affects 80–90 % of patients with plaque Psoriasis, and is even more prevalent in patients with psoriatic arthritis. This review is the result of a systemic approach to the literature and covers topical, intralesional, conventional systemic, and biologic systemic treatments, as well as non-pharmacological treatment options for Nail Psoriasis. The available evidence suggests that all anti-tumor necrosis factor-α, anti-interleukin (IL)-17, and anti-IL-12/23 antibodies which are available for plaque Psoriasis and psoriatic arthritis are highly effective treatments for Nail Psoriasis. Conventional systemic treatments, including methotrexate, cyclosporine, acitretin, and apremilast, as well as intralesional corticosteroids, can also be effective treatments for Nail Psoriasis. Topical treatments, including corticosteroids, calcipotriol, tacrolimus, and tazarotene, have also been shown to have a position in the treatment of Nail Psoriasis, particularly in mild cases. Finally, non-pharmacological treatment options, including phototherapy, photodynamic therapy, laser therapy, and several radiotherapeutic options, are also reviewed but cannot be advised as first-line treatment options. Another conclusion of this review is that the lack of a reliable core set of outcomes measures for trials in Nail Psoriasis hinders the interpretation of results, and is urgently needed.
-
Nail Psoriasis, the unknown burden of disease
Journal of the European Academy of Dermatology and Venereology, 2014Co-Authors: K.m.g. Klaassen, P.c.m. Van De Kerkhof, Marcel C. PaschAbstract:BACKGROUND: Psoriasis can be found at several different localizations which may be of various impact on patients' quality of life (QoL). One of the easy visible, and difficult to conceal localizations are the Nails. OBJECTIVE: To achieve more insight into the QoL of psoriatic patients with Nail Psoriasis, and to characterize the patients with Nail involvement which are more prone to the impact of the Nail alterations caused by Psoriasis. METHOD: A self-administered questionnaire was distributed to all members (n = 5400) of the Dutch Psoriasis Association. The Dermatology Life Quality Index (DLQI) and the Nail Psoriasis Quality of life 10 (NPQ10) score were included as QoL measures. Severity of cutaneous lesions was determined using the self-administered Psoriasis area and severity index (SAPASI). RESULTS: Patients with Nail Psoriasis scored significantly higher mean scores on the DLQI (4.9 vs. 3.7, P =
-
Scoring Nail Psoriasis.
Journal of the American Academy of Dermatology, 2014Co-Authors: Karlijn M.g. Klaassen, Peter C.m. Van De Kerkhof, Maarten T. Bastiaens, Leon G.j.m. Plusjé, Robert Baran, Marcel C. PaschAbstract:Background Scoring systems are indispensable in evaluating the severity of disease and monitoring treatment response. Objective We sought to evaluate the competence of various Nail Psoriasis severity scoring systems and to develop a new scoring system. Methods The authors conducted a prospective, observational, single-point study of 36 patients given the diagnosis of fingerNail Psoriasis. Seven scoring systems were evaluated: Nail Psoriasis Severity Index (NAPSI), modified NAPSI, target NAPSI, Psoriasis Nail Severity Score, Nail Area Severity, Baran, and Cannavo et al. All tools were correlated with the Physician Global Assessment. Obtained information was integrated into the Nijmegen–Nail Psoriasis Activity Index tooL (N-Nail), and interrater and intrarater reliability was assessed. Results Physician Global Assessment showed an acceptable correlation with the scoring system designed by Baran ( r = 0.735, P r = 0.734, P r = 0.203, P > .05). The correlation between Physician Global Assessment and the N-Nail was 0.861 ( P Limitations Sample size was limited. Conclusion An adequate Nail Psoriasis scoring system is needed, as studies of treatments for Nail Psoriasis are on the horizon. Clinical severity of Nail Psoriasis was best reflected by the N-Nail, followed by the Baran system and the Psoriasis Nail Severity Score.
Akimichi Morita - One of the best experts on this subject based on the ideXlab platform.
-
Patient-relevant needs and treatment goals in Nail Psoriasis
Quality of Life Research, 2016Co-Authors: C. Blome, Antonio Costanzo, Esteban Daudén, Carlos Ferrándiz, Giampiero Girolomoni, Robert Gniadecki, Lars Iversen, Alan Menter, K. Michaelis-wittern, Akimichi MoritaAbstract:Purpose Patient-centered health care implies that medical decisions are made jointly by physician and patient, based on patient needs. Aims were to (a) identify treatment goals for a new questionnaire on patient needs and benefits in Nail Psoriasis treatment; (b) analyze the importance of treatment goals in patients with Nail Psoriasis in general and in defined subgroups; and (c) determine the association between overall treatment goal importance and quality of life. Methods The study comprised the following steps: qualitative survey on needs and burdens in 120 patients; development of items by an interdisciplinary expert group; item testing in 55 patients in four countries; revision of the questionnaire and assessment in 203 patients in six countries (Germany, Denmark, Italy, Spain, USA, Japan). The percentage of patients rating the goals as ‘quite/very important’ was compared between various patient subgroups. Results Based on 692 free-text statements, 26 items were developed which were reduced to 24 items after pilot testing. Each of these treatment goals applied to the majority of patients in the multi-center study. Goal importance increased with severity of Nail Psoriasis, but not with age or disease duration. Manual dexterity and social interaction were of particular importance. Goal importance and quality of life were associated, but not redundant ( r = 0.612, p
-
Patient-relevant Needs and Treatment Goals in Nail Psoriasis
Quality of Life Research, 2015Co-Authors: Christine Blome, Antonio Costanzo, Esteban Daudén, Carlos Ferrándiz, Giampiero Girolomoni, Robert Gniadecki, Lars Iversen, Alan Menter, K. Michaelis-wittern, Akimichi MoritaAbstract:Purpose Patient-centered health care implies that medical decisions are made jointly by physician and patient, based on patient needs. Aims were to (a) identify treatment goals for a new questionnaire on patient needs and benefits in Nail Psoriasis treatment; (b) analyze the importance of treatment goals in patients with Nail Psoriasis in general and in defined subgroups; and (c) determine the association between overall treatment goal importance and quality of life.
Ferayi Kaharaman - One of the best experts on this subject based on the ideXlab platform.
-
pulsed dye laser in the treatment of Nail Psoriasis
Dermatologic Surgery, 2010Co-Authors: Yasemin Oram, Erkan Koyuncu, Yelda Karincaoglu, Ferayi KaharamanAbstract:BACKGROUNDThe treatment options for Nail Psoriasis have been limited, and the management of Nail Psoriasis has been challenging for physicians.OBJECTIVESTo evaluate the effect of pulsed dye laser (PDL) in the treatment of Nail Psoriasis.METHODSPsoriatic Nails of five patients were treated using PDL
Alexis Ogdie - One of the best experts on this subject based on the ideXlab platform.
-
Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
The Journal of rheumatology, 2020Co-Authors: Philip J. Mease, Mei Liu, Sabrina Rebello, Robert Mclean, Blessing Dube, Meghan Glynn, Peter Hur, Alexis OgdieAbstract:OBJECTIVE To examine the association of Nail Psoriasis with disease activity, quality of life, and work productivity in patients with psoriatic arthritis (PsA). METHODS All patients with PsA who enrolled in the Corrona PsA/Spondyloarthritis Registry between March 2013 and October 2018 and had data on physician-reported Nail Psoriasis were included and stratified by presence vs absence of Nail Psoriasis at enrollment. Patient demographics, disease activity, quality of life, and work productivity at enrollment were compared between patients with vs without Nail Psoriasis using t-tests or Wilcoxon rank-sum tests for continuous variables and χ2 or Fisher exact tests for categorical variables. RESULTS Of the 2841 patients with PsA included, 1152 (40.5%) had Nail Psoriasis and 1689 (59.5%) did not. Higher proportions of patients with Nail Psoriasis were male (51.9% vs 44.1%) and disabled from working (12.3% vs 7.8%) compared with patients without Nail Psoriasis (all P < 0.05). Patients with Nail Psoriasis had higher disease activity than those without Nail Psoriasis, including higher tender and swollen joint counts, worse Disease Activity in Psoriatic Arthritis and Psoriatic Arthritis Disease Activity Score values, and increased likelihood of having enthesitis and dactylitis (all P< 0.05). Patients with Nail Psoriasis had worse pain, fatigue, and work and activity impairment than those without Nail Psoriasis (all P < 0.05). CONCLUSION Patients with PsA who have Nail Psoriasis had worse disease activity, quality of life, and work productivity than those without Nail involvement, emphasizing the importance of identification and management of Nail disease in patients with PsA.
-
sat0388 characterization of patients with psoriatic arthritis and Nail Psoriasis data from the corrona psoriatic arthritis spondyloarthritis psa spa registry
Annals of the Rheumatic Diseases, 2019Co-Authors: Philip J. Mease, Mei Liu, Sabrina Rebello, Robert Mclean, Blessing Dube, Meghan Glynn, Peter Hur, Alexis OgdieAbstract:Background Nail disease is an important feature of PsA and may even precede the disease by many years.1 Nail Psoriasis is considered one of the 6 disease domains of PsA2; however, there have been limited real-world studies that have examined characteristics of patients with PsA and Nail Psoriasis, particularly in the United States. Objectives To characterize the disease activity, quality of life, and work productivity of patients with PsA with and without Nail Psoriasis in the US-based Corrona PsA/SpA Registry. Methods This study included all patients in the Corrona PsA/SpA registry enrolled between March 2013 and October 2018 with a diagnosis of PsA who had non-missing data on physician-reported Nail Psoriasis. Patients were stratified by presence vs absence of Nail Psoriasis at the time of enrollment, defined as a non-zero response on the Nail Psoriasis visual analog scale (VAS) of 0–100. Descriptive analyses of patient demographics, disease activity, quality of life, and work productivity were assessed at enrollment and compared between Nail Psoriasis groups using t-tests or Wilcoxon rank-sum tests for continuous variables and χ2 or Fisher’s exact tests for categorical variables. Results A total of 2841 patients with PsA met the inclusion criteria, including 1152 patients (40.5%) with Nail Psoriasis and 1689 patients (59.5%) without Nail Psoriasis at enrollment. Patients with and without Nail Psoriasis were similar in terms of demographic and clinical characteristics; however, patients with Nail Psoriasis were slightly younger (53.1 vs 54.4 years) and more likely to be male (51.9% vs 44.1%) and have a higher history of depression (17.8% vs 13.3%) compared with patients without Nail Psoriasis (all P Conclusion PsA patients with Nail Psoriasis at the time of registry enrollment had worse disease activity, quality of life, and work productivity compared with those patients without Nail involvement. These findings emphasize the importance of identification and management of Nail disease in patients with PsA. References [1] Gladman DD, et al. Ann Rheum Dis. 2005;64(suppl 2):ii14-7. [2] Coates LC, et al. Arthritis Rheumatol. 2016;68(5):1060-71. Acknowledgement This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Novartis, with financial support provided by Novartis. Disclosure of Interests Philip J Mease Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB, Peter Hur Employee of: Peter Hur is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, Mei Liu Employee of: M. Liu is an employee of Corrona, LLC., Sabrina Rebello Employee of: Corrona, LLC, Robert McLean: None declared, Blessing Dube Employee of: B. Dube is an employee of Corrona, LLC., Meghan Glynn Employee of: M. Glynn is an employee of Corrona, LLC., Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda
Yasemin Oram - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Nail Psoriasis: common concepts and new trends.
Dermatology Research and Practice, 2013Co-Authors: Yasemin Oram, A. Deniz AkkayaAbstract:The lifetime incidence of Nail involvement in psoriatic patients is estimated to be 80–90%, and the Nails can be affected in 10% to 55% of psoriatic patients. Psoriasis may also solely involve the Nails, without any other skin findings, in which the treatment can be more challenging. Nail Psoriasis may lead to considerable impairment in quality of life due to aesthetic concerns and more importantly limitations in daily activities resulting from the associated pain, which may be overlooked by the physicians. Several topical and systemic treatment modalities, as well as radiation and light systems, have been used in the treatment of Nail Psoriasis. In the last decade, the introduction of biologic agents and the utilization of laser systems have brought a new insight into the treatment of Nail Psoriasis. This paper focuses on the recent advances, as well as the conventional methods, in treating Nail Psoriasis in adults and children, in reference to an extensive literature search.
-
pulsed dye laser in the treatment of Nail Psoriasis
Dermatologic Surgery, 2010Co-Authors: Yasemin Oram, Erkan Koyuncu, Yelda Karincaoglu, Ferayi KaharamanAbstract:BACKGROUNDThe treatment options for Nail Psoriasis have been limited, and the management of Nail Psoriasis has been challenging for physicians.OBJECTIVESTo evaluate the effect of pulsed dye laser (PDL) in the treatment of Nail Psoriasis.METHODSPsoriatic Nails of five patients were treated using PDL
